MX2022016533A - Composiciones que comprenden compuestos psicoactivos de organismos psicoactivos. - Google Patents

Composiciones que comprenden compuestos psicoactivos de organismos psicoactivos.

Info

Publication number
MX2022016533A
MX2022016533A MX2022016533A MX2022016533A MX2022016533A MX 2022016533 A MX2022016533 A MX 2022016533A MX 2022016533 A MX2022016533 A MX 2022016533A MX 2022016533 A MX2022016533 A MX 2022016533A MX 2022016533 A MX2022016533 A MX 2022016533A
Authority
MX
Mexico
Prior art keywords
psychoactive
organisms
compounds
compositions
extraction
Prior art date
Application number
MX2022016533A
Other languages
English (en)
Inventor
Benjamin Lightburn
Ryan Moss
Lisa Ranken
Original Assignee
Psilo Scientific Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA3088384A external-priority patent/CA3088384C/en
Priority claimed from CA3097246A external-priority patent/CA3097246C/en
Priority claimed from CA3101765A external-priority patent/CA3101765A1/en
Priority claimed from CA3103707A external-priority patent/CA3103707C/en
Application filed by Psilo Scientific Ltd filed Critical Psilo Scientific Ltd
Priority claimed from PCT/CA2021/050813 external-priority patent/WO2021253116A1/en
Publication of MX2022016533A publication Critical patent/MX2022016533A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/078—Psilocybe
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/02—Solvent extraction of solids
    • B01D11/0215—Solid material in other stationary receptacles
    • B01D11/0253—Fluidised bed of solid materials
    • B01D11/0257—Fluidised bed of solid materials using mixing mechanisms, e.g. stirrers, jets
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/02—Solvent extraction of solids
    • B01D11/028—Flow sheets
    • B01D11/0284—Multistage extraction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/02—Solvent extraction of solids
    • B01D11/0288—Applications, solvents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/02—Solvent extraction of solids
    • B01D11/0292—Treatment of the solvent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Esta invención se relaciona con la extracción de compuestos psicoactivos de organismos para su uso en medicina. La extracción se lleva a cabo con un ácido fuerte o una base fuerte para promover o inhibir la desfosforilación. El extracto en forma de suspensión se estandariza con un excipiente agregado de modo que cuando se seca, la composición en polvo tiene una concentración específica de alcaloides psicoactivos totales, con una proporción conocida de alcaloides psicoactivos fosforilados a desfosforilados.
MX2022016533A 2020-06-17 2021-06-14 Composiciones que comprenden compuestos psicoactivos de organismos psicoactivos. MX2022016533A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202063040317P 2020-06-17 2020-06-17
US202063046089P 2020-06-30 2020-06-30
CA3088384A CA3088384C (en) 2020-06-17 2020-07-29 Extraction of psychoactive compounds from psilocybin fungus
CA3089455A CA3089455C (en) 2020-06-17 2020-08-07 Methanol-based extraction of psychoactive compounds from fungus
CA3097246A CA3097246C (en) 2020-10-23 2020-10-23 Process for obtaining a purified psychoactive alkaloid solution
CA3101765A CA3101765A1 (en) 2020-12-04 2020-12-04 Psychoactive alkaloid extraction and composition with controlled dephosphorylation
CA3103707A CA3103707C (en) 2020-12-18 2020-12-18 Standardized psychoactive alkaloid extract composition
PCT/CA2021/050813 WO2021253116A1 (en) 2020-06-17 2021-06-14 Compositions comprising psychoactive compounds from psychoactive organisms

Publications (1)

Publication Number Publication Date
MX2022016533A true MX2022016533A (es) 2023-04-05

Family

ID=79022851

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016533A MX2022016533A (es) 2020-06-17 2021-06-14 Composiciones que comprenden compuestos psicoactivos de organismos psicoactivos.

Country Status (6)

Country Link
US (4) US11331357B2 (es)
EP (1) EP4161546A4 (es)
AU (7) AU2021290454B2 (es)
BR (1) BR112022025780A2 (es)
IL (9) IL305632B2 (es)
MX (1) MX2022016533A (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114787363A (zh) 2019-10-01 2022-07-22 恩派瑞安神经科学公司 对真菌进行遗传工程化以调节色胺表达
CA3197443C (en) 2020-12-28 2024-10-22 Psilo Scientific Ltd. METHODS FOR EXTRACTION OF PSYCHOACTIVE ALKALOIDS AND RELATED PREPARATION IN TRANSMUCOSAL FORMS
US20220370413A1 (en) 2021-03-06 2022-11-24 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
CA3127180C (en) * 2021-08-06 2024-03-05 Psilo Scientific Ltd. Pre-evaporation standardization of extracted psychoactive compounds
CA3232692A1 (en) * 2021-09-28 2023-04-06 Joseph Girardi Chilled juice extraction processes and products using psychedelic and functional mushrooms
CA3133547C (en) * 2021-10-07 2024-07-02 Psilo Scientific Ltd. LIQUID-LIQUID EXTRACTION OF PURIFIED PSYCHOACTIVE ALKALOIDS
WO2023130078A2 (en) 2021-12-31 2023-07-06 Empyrean Neuroscience, Inc. Genetically modified mycelium for producing psychotropic alkaloids
WO2023225186A1 (en) * 2022-05-18 2023-11-23 Chemtor, Lp Extraction of psilocybin and psilocin
GB202313750D0 (en) 2023-09-08 2023-10-25 Psyence Group Inc A process for obtaining a purified psychoactive alkaloid
AU2024367931A1 (en) 2023-10-23 2026-02-26 Reconnect Labs Ag Pharmaceutical formulations comprising 5-meo-dmt and their therapeutic uses
US12611417B1 (en) * 2025-06-03 2026-04-28 Convergent Health Sciences LLC: Compositions and methods to inhibit acid-catalyzed dephosphorylation of phosphoryloxytryptamines

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE264023C (es)
LU36879A1 (es) 1958-02-21
GB911946A (en) * 1958-02-21 1962-12-05 Sandoz Ltd Psilocybin and psilocin and processes for their preparation
DD264023A1 (de) * 1987-07-17 1989-01-18 Akad Wissenschaften Ddr Verfahren zur extraktion von indolalkaloiden aus pilzmaterial
US6596298B2 (en) 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
JP2005522460A (ja) 2002-02-28 2005-07-28 マリンクロッド・インコーポレイテッド 逆相分取用クロマトグラフィーを用いる少なくとも１種の麻薬性アルカロイドの分離および精製のための方法およびシステム
SE0302947D0 (sv) 2003-01-24 2003-11-07 Magle Ab A composition material for transmucosal delivery
AU2007295179B2 (en) 2006-09-15 2013-05-30 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
CN101292727A (zh) * 2008-05-30 2008-10-29 曹晋忠 菌类乙醇提取物的粉体制备方法
JP5806287B2 (ja) 2010-03-30 2015-11-10 フォスファジェニクス リミティド 経皮送達パッチ
ES2898173T3 (es) 2014-06-30 2022-03-04 Syqe Medical Ltd Dispositivos y sistemas para la administración pulmonar de principios activos
US20180021326A1 (en) 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
NL2018190B1 (en) 2017-01-18 2018-07-26 Procare Beheer B V Psilocybin or psilocin in combination with cannabinoid
CA3052974A1 (en) 2017-02-09 2018-08-16 CaaMTech, LLC Compositions and methods comprising a psilocybin derivative
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2019099745A1 (en) * 2017-11-16 2019-05-23 CaaMTech, LLC Compositions comprising a psilocybin derivative and a cannabinoid
CN109528846A (zh) * 2018-12-27 2019-03-29 贵州理工学院 一种植物中生物碱提取纯化的方法
EP4230195A1 (en) 2019-03-07 2023-08-23 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations
US20220194992A1 (en) 2019-04-26 2022-06-23 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding aav2.5 vector
CA3097246C (en) 2020-10-23 2023-03-28 Psilo Scientific Ltd. Process for obtaining a purified psychoactive alkaloid solution
US20220304980A1 (en) 2019-07-04 2022-09-29 SW Holdings, Inc Metered dosing compositions and methods of use of psychedelic compounds
US11208117B2 (en) 2019-07-09 2021-12-28 Refraction Ai, Inc. Method and system for autonomous vehicle control
WO2021159213A1 (en) * 2020-02-12 2021-08-19 Neonmind Biosciences Inc. Method for producing an extract of mushroom and mushroom extract made therefrom
US11382942B2 (en) 2020-06-17 2022-07-12 Psilo Scientific Ltd. Extraction of psychoactive compounds from psilocybin fungus
CA3124367C (en) 2020-06-17 2022-04-26 Psilo Scientific Ltd. Aqueous extraction of psychoactive compounds from psilocybin fungus
US20220054402A1 (en) 2020-11-05 2022-02-24 Richard C Kaufman Compositions and methods for extracting, stabilizing, and manufacturing stable dosage forms of psilocin, psychedelic drugs, entheogens, and medicinal mushrooms as nano-dimensional drug delivery structures
US20220331292A1 (en) 2021-04-16 2022-10-20 Callitas Health Inc. Compositions and methods for delivery of psilocin and prodrugs thereof
US12440472B2 (en) 2021-06-16 2025-10-14 Intelgenx Corp. Stable tryptamine oral films

Also Published As

Publication number Publication date
IL297791B1 (en) 2025-06-01
AU2022291410A1 (en) 2023-02-02
US11298388B2 (en) 2022-04-12
IL305632B1 (en) 2025-04-01
AU2022291413B2 (en) 2024-02-22
IL299452B1 (en) 2024-09-01
AU2022291414B2 (en) 2023-12-07
US20210393716A1 (en) 2021-12-23
IL298561B1 (en) 2025-06-01
AU2022291416A1 (en) 2023-02-02
IL299453B1 (en) 2024-08-01
AU2022291413A1 (en) 2023-02-02
IL297791B2 (en) 2025-10-01
IL305632A (en) 2023-11-01
IL299449B1 (en) 2025-07-01
IL299451A (en) 2023-02-01
IL298561B2 (en) 2025-10-01
AU2023285751B2 (en) 2024-06-06
IL299450A (en) 2023-02-01
AU2022291414A1 (en) 2023-02-02
US11642385B2 (en) 2023-05-09
AU2022291411B2 (en) 2023-12-07
AU2021290454B2 (en) 2024-01-11
IL305632B2 (en) 2025-08-01
AU2021290454A1 (en) 2023-01-19
AU2023285751A1 (en) 2024-01-18
EP4161546A1 (en) 2023-04-12
EP4161546A4 (en) 2024-10-09
IL299448A (en) 2023-02-01
IL298561A (en) 2023-01-01
IL299453B2 (en) 2024-12-01
IL299452A (en) 2023-02-01
US11331357B2 (en) 2022-05-17
IL299453A (en) 2023-02-01
IL299451B2 (en) 2024-12-01
IL297791A (en) 2022-12-01
IL299451B1 (en) 2024-08-01
IL299448B1 (en) 2025-07-01
US11571450B2 (en) 2023-02-07
AU2022291410B2 (en) 2024-04-04
IL299452B2 (en) 2025-01-01
IL299448B2 (en) 2025-11-01
IL299449B2 (en) 2025-11-01
US20220040246A1 (en) 2022-02-10
US20220226405A1 (en) 2022-07-21
IL299449A (en) 2023-02-01
US20220202886A1 (en) 2022-06-30
BR112022025780A2 (pt) 2023-01-10
AU2022291411A1 (en) 2023-02-02
AU2022291416B2 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
ZA202102999B (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
BR112022025780A2 (pt) Método para gerar um extrato de alcaloide psicoativo, método para gerar um extrato de alcaloide psicoativo fosforilado e método para gerar um extrato de alcaloide psicoativo desfosforilado
MX2022016531A (es) Extraccion de compuestos psicoactivos del hongo psicodelico.
JOP20230272A1 (ar) مركبات تثبيط rip1 وطرق لتحضير واستخدامها
TN2012000265A1 (en) Triazolopyridines
MX2013002713A (es) Imidazopiridazinas sustituidas.
BRPI0610876A2 (pt) composto, mÉtodos de inibir uma atividade de uma jak cinase, de tratar uma doenÇa autoimune mediada por cÉlula t, de tratar ou prevenir rejeiÇço ao transplante de aloenxerto em um receptor de transplante, de inibir uma cascata de transduÇço de sinal que jak3 cinase desempenha um papel e de tratar ou prevenir uma doenÇa mediada por jak cinase, formulaÇço farmacÊutica, e, kit
WO2017204445A3 (ko) Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
NZ630457A (en) Compounds useful as inhibitors of atr kinase
HK1211942A1 (en) Pyrazolopyrimidine compounds as kinase inhibitors
MX2009009843A (es) Compuestos espiro sustituidos como inhibidores de la angiogenesis.
NZ603456A (en) 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer
PE20171338A1 (es) Compuestos y composiciones como inhibidores de quinasa raf
EA202090448A1 (ru) Дигидрооксадиазиноны
MA46608B1 (fr) Formulation liposomale utile pour le traitement du cancer
CY1115974T1 (el) Παραγωγα πυραζολοκινολινης ως αναστολεις dna-pk
MX2023000577A (es) Compuesto de pirazolopirimidina usado como inhibidor de atr cinasa.
TN2014000433A1 (en) Dosage regimen for a pi-3 kinase inhibitor
MX2023003516A (es) Inhibidores no covalentes de la cinasa dependiente de ciclina 7 (cdk7).
PE20190778A1 (es) Derivados de eter ciclico de pirazolo[1,5-a]pirimidin-3-carboxiamida
PH12019500478A1 (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
EA202191588A1 (ru) Замещенные ксантиновые производные
WO2017021974A3 (en) NOVEL SYNERGISTIC COMPOSITION OF LECITHIN AND LYSOLECHINE TO IMPROVE BIOAVAILABILITY AND SOLUBILITY OF HYDROPHOBIC COMPOUNDS AND EXTRACTS
MX2019014102A (es) Tablero de yeso y suspension espesa de yeso formada usando un compuesto que contiene fosforo.
MX2022016530A (es) Extraccion base metanol de compuestos psicoactivos de hongos.